For infants and young children, which aerosol delivery method—various types of nebulisers, a pressurised metered‑dose inhaler (MDI) with a valved spacer, or a dry‑powder inhaler (DPI)—provides the most effective and appropriate drug delivery?

Aerosol Drug Delivery to Infants and Pediatric Patients

Direct Recommendation

For infants and children <4 years old, use a pressurized metered-dose inhaler (pMDI) with a valved holding chamber (spacer) with face mask as the first-line delivery method; for children ≥4 years old who can demonstrate adequate inspiratory flow, dry powder inhalers (DPIs) become an option, while nebulizers should be reserved for patients who cannot coordinate pMDI use or require high-dose bronchodilator therapy in acute exacerbations. 1, 2

---

Age-Based Device Selection Algorithm

Infants and Children <4 Years Old

• Primary choice: pMDI + valved holding chamber (VHC) + face mask 1, 2

  • Children in this age group have less difficulty with face mask delivery systems
  • The VHC improves lung delivery by 50% compared to MDI alone, even though face masks reduce delivery by approximately 50% compared to mouthpieces 1
  • Requires 3-5 tidal inhalations per actuation with tight mask fit 1
  • Actuate only once into spacer/VHC per inhalation 1

• Alternative: Nebulizer 1, 2

  • Use when patient cannot coordinate pMDI with VHC
  • Less dependent on patient coordination and cooperation 1
  • Delivery method of choice for cromolyn sodium in young children 1
  • Important caveat: Nebulizers are time-consuming, bulky, and have significant output variability between devices 1

Children 2-4 Years Old (Transitional Age)

• Preferred: pMDI + VHC without face mask 3
  • Children ≥2 years can typically use spacer without mask if properly trained
  • Mouthpiece delivery is preferred when feasible to maximize lung deposition

Children ≥4 Years Old

• Options expand to include DPIs 1, 2

  • DPIs require sufficient inspiratory flow for the specific device
  • Patient must demonstrate adequate technique before prescribing
  • FDA-approved options include fluticasone DPI and salmeterol DPI (alone or combined with ICS) for ages >4 years 1

• pMDI + VHC remains appropriate for those who cannot coordinate DPI use 2

• Rotahaler can be taught to children 3-4 years old 3

---

Device-Specific Considerations

pMDI with Valved Holding Chamber (VHC)

Advantages:

• Equivalent efficacy to nebulizers for bronchodilators in mild-to-moderate exacerbations 1, 4
• Reduces oropharyngeal deposition, decreasing risk of thrush with inhaled corticosteroids 1
• Decreases systemic availability of ICS with higher oral absorption 1
• More convenient and less time-consuming than nebulizers 4

Critical technique points:

• Use slow, deep inhalation (30 L/min or 3-5 seconds) followed by 10-second breath-hold for children ≥4 years 1
• For infants/young children: tidal breathing through spacer with 3-5 inhalations per actuation 1, 5
• Rinse plastic VHCs monthly with dilute household detergent (1:5000 or drops per cup of water) and air-dry to reduce static charge 1

Important caveat: Avoid face masks when administering inhaled steroids to prevent facial skin and eye exposure 6

Nebulizers

When to use:

• Acute asthma requiring high-dose bronchodilators 5
• Any age patient who cannot use pMDI with VHC 1
• Delivery of cromolyn sodium in young children 1

Limitations:

• As effective as pMDI + VHC for bronchodilators in mild-to-moderate exacerbations, but data in severe exacerbations are limited 1
• Significant inter-device and intra-device output variability 1, 6
• Time-consuming, expensive, and bulky 1
• Potential for bacterial contamination if not cleaned properly 1
• Low lung deposition efficiency: only 0.22-1.74% of initial dose reaches lungs in infants 7

Dry Powder Inhalers (DPIs)

Restrictions:

• Only for children ≥4 years old who can demonstrate sufficient inspiratory flow 2
• Driven by patient's peak inspiratory flow, making them inappropriate for younger children 5
• Require proper technique demonstration before prescribing

---

Comparative Efficacy Data

pMDI + Spacer vs. Nebulizer

Key finding: Comparable efficacy for both acute and maintenance therapy 4

• Multiple studies demonstrate equivalent bronchodilator effects between pMDI + spacer and nebulizers 1, 4
• This contradicts the common misconception that nebulizers are more effective 4
• pMDI + spacer offers advantages of convenience, lower cost, and reduced treatment time

Lung Deposition in Infants

Research shows extremely low lung deposition with both delivery methods in ventilated and non-ventilated infants with bronchopulmonary dysplasia 7:

• pMDI: 0.67-0.98% of actuated dose
• Nebulizer: 0.22-0.28% of initial reservoir dose
• Marked inter-subject variability with both methods
• Aerosol tends to deposit in central lung regions

---

Common Pitfalls and How to Avoid Them

Misconception #1: Nebulizers Are More Effective

Reality: pMDI + spacer achieves comparable efficacy with greater convenience 4

Misconception #2: Correct Inhaler Use Is Easy

Reality: Many children use inhalers incorrectly even after instruction 4

• Solution: Healthcare providers must teach and periodically re-teach correct technique 2
• Correct technique deteriorates over time and requires repeated instruction 4

Misconception #3: One-Time Teaching Is Sufficient

Reality: Inhalation technique must be monitored and reinforced regularly 2, 4

Critical Error: Using "Blow-By" Technique

Do not use blow-by for aerosol administration 2

• This method is ineffective and wastes medication

Device-Drug Mismatch

Use nebulizer/drug combinations as FDA-approved 2

• Not all drugs are approved for all delivery devices
• Verify compatibility before prescribing

---

Practical Implementation Strategy

Step 1: Age Assessment

• <4 years → pMDI + VHC + face mask (or nebulizer if unable to coordinate)
• ≥4 years → Assess inspiratory flow capability

Step 2: Capability Assessment for Children ≥4 Years

• Can demonstrate adequate inspiratory flow? → DPI option available
• Cannot coordinate technique? → Continue pMDI + VHC or use nebulizer

Step 3: Clinical Context

• Acute exacerbation requiring high-dose bronchodilator → Nebulizer or multiple pMDI doses via spacer 5
• Maintenance therapy → pMDI + VHC preferred for convenience 4
• Inhaled corticosteroids → Avoid face masks; use mouthpiece with spacer to minimize oropharyngeal deposition 1, 6

Step 4: Education and Monitoring

• Demonstrate correct technique at every visit 2
• Reassess technique periodically as it deteriorates over time 4
• Use unit-dose medications to reduce infection risk 2

---

Special Populations

Patients with Glaucoma

Avoid face masks or ensure very tight seal when administering anticholinergic agents 6

Patients Requiring Respiratory Support

Either nebulizer or pMDI can be used during noninvasive ventilation 2

Patients Unable to Use Mouthpiece

Aerosol masks are the interface of choice 2

---

Medication-Specific Considerations

FDA-approved long-term control medications by age 1:

• Budesonide nebulizer solution: 1-8 years
• Fluticasone DPI: >4 years
• Salmeterol DPI (alone or with ICS): >4 years
• Montelukast: Chewable tablets 2-6 years; granules ≥1 year

Doses vary considerably among devices and age groups 1